High Tide Closes Acquisition of Jimmy’s Cannabis Shop BC

By -
CALGARY, Alberta--(BUSINESS WIRE)--High Tide Inc. (“High Tide” or the “Company”) (Nasdaq: HITI) (TSXV: HITI) (FSE: 2LYA), a leading retail-focused cannabis company with bricks-and-mortar as well as global e-commerce assets, announced today that further to its press release dated September 29, 2022, the Company has completed its acquisition (the “Acquisition”) of 100% of the equity interest of 1171882 B.C. Ltd., operating as Jimmy’s Cannabis Shop BC (“Jimmy’s”), resulting in High Tide’s acquisition of two retail cannabis stores currently operated by Jimmy’s in British Columbia (the “Stores”) for $5.3 Million (the “Transaction”). The Stores are located at 1225 Cranbrook Street North, Cranbrook and 1543 Victoria Street, Prince George. The Cranbrook store is located near the base camp of the Kootenay Rockies and is within a short drive of award-winning golf courses and nature trails. It is also situated within a commercial complex that includes a prominent local grocery store as well as a multinational hotel chain. The Prince George store is situated within the largest city in northern British Columbia, which is also close to the crossroads of provincial highways 16 and 97. The store itself is located within a commercial plaza including a national pharmacy chain and a major discount clothing retailer. The closing of the Transaction brings High Tide’s nationwide store count to 149, including six in British Columbia. The Company also anticipates the organic opening of its location in Kamloops, BC, imminently.  For the trailing four months ended May 31, 2022, the Stores generated annualized revenue of $5.4 Million and annualized Adjusted EBITDA1 of $1.0 Million. The purchase price represents 5.25x annualized Adjusted EBITDA for the trailing four months ended May 31, 2022. TRANSACTION DETAILS The Acquisition was completed pursuant to the terms of a share purchase agreement, dated September 28, 2022 (the “Acquisition Agreement”). High Tide acquired 100% of Jimmy’s for 2,595,533 common shares of High Tide (each, a “High Tide Share”) valued at $5.3 Million (the “Share Consideration”), on the basis of a deemed price of C$2.0365 per High Tide Share. The purchase price is subject to a post-closing working capital adjustment provision, to address any increase or decrease of working capital, inventory or cash estimated as of the closing date. The closing of the Transaction remains subject to final approval from the TSX Venture Exchange (“TSXV”). Pursuant to the Acquisition Agreement, 70% of the High Tide Shares issued are subject to a four month hold. ABOUT JIMMY’S Jimmy’s strives to find a balance between being a boutique and a neighbourhood store using a heritage theme that is both reflective of the individual communities in which it does business and chronicling Jimmy’s cultural relationship with cannabis over the past 100 years. At Jimmy’s, we love to have fun, but we also have the knowledge, background, and training to ensure clients can purchase responsibly.   ABOUT HIGH TIDE High Tide is a leading retail-focused cannabis company with bricks-and-mortar as well as global e-commerce assets. The Company is the largest non-franchised
http://dlvr.it/Sg6wNW

Comments

Post a Comment

Popular posts from this blog

Hempy 2014!

By -
Image
I started 2013 with a basement full of weed and an empty bank account. I don’t know of any Seattle growers that actually got rich from growing pot this year. I think a lot of us unemployed corporate types who were laid off saw the opportunity to work for ourselves until the state could figure out what to do with the future of medical and voter approved recreational pot. A year later, the future of  medical marijuana in Washington State is still tenuous.  I have personally witnessed healing in people who use cannabis as medicine and I think it’s a crime that providers have been thrown in jail for helping others. Cannabis IS medicine and we have a God-given right to have access to it. Dispensary “donations” were my main source of income in 2013. I make half of what I used to back in my VC-funded days, but I don’t care. Money is not it. Helping people, and loving what you do on a daily basis where it’s at, man. The meaning of life is to be of service to others. Working
Read more

Coming Out of the Pot Closet

By -
Image
I have to vacuum before my mother arrives from Arizona. I’m 40-something years old and I still want her housekeeping approval. While we’re close, and speak on the phone every week, we haven’t seen each other 1:1 for a while. I’m freaking out because I think she’ll have an aneurysm when I tell her how I’ve been paying my bills the past three years. Garden of Eve The time has arrived for me to come out of the Pot Closet to my mother. How did I get here? I was laid off from my event-planning job while dating a “normal-looking” guy, who owned his own landscaping business. “Larry” also happen to own a basement full of marijuana plants for extra spending money (on prostitutes, as it turns out, but that’s a different blog post). He taught me everything I know about being a Pharmer -- from cloning and transplanting, to providing my babies with the proper nutrients and watering techniques.  I learned a lot – about the miraculous cannabis plant, and about the lying, cheating asshol
Read more

PureTech Provides End of Year Report on Key Progress

By -
Image
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today reported on the key progress made across its Wholly Owned Programs1 and Founded Entities2 in 2022. Daphne Zohar, Founder and Chief Executive Officer of PureTech, commented: “2022 has been a particularly successful and productive year in both crystallizing value and shaping the future of PureTech. Our primary focus is to progress our Wholly Owned Pipeline to commercialization and deliver new classes of medicines for patients with serious, debilitating conditions. We are advancing toward this goal by deepening our commitment to programs with compelling clinical data that are moving into late-stage studies and that we believe have the potential for broad impact. “Over the next 12 months, we anticipate multiple important catalysts that will further guide how we prioritize o
Read more